VC-backed public offerings at lowest ebb since 2011

Six venture-backed IPOs raised just $574.5 million in the first quarter of 2016, according to the Exit Poll Report by analysts at Thomson Reuters and the National Venture Capital Association. This marks the slowest quarter for these types of IPOs since the third quarter of 2011. In all, 79 venture-backed M&A deals were reported in the first quarter, 20 of which reported an aggregate deal value of $4.8 billion, according to the study. "Due to a sustained period of turbulence in the public markets at the start of the year combined with non-traditional investors making direct investments into later-stage startups, venture-backed IPO activity in the first quarter was nearly non-existent," said Bobby Franklin, president and CEO of NVCA. This also comes a week after new figures revealed that the Nasdaq Biotechnology Index was down 23% in the first quarter. Release

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.